J. Eron

发表

Raltegravir with optimized background therapy for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine

J. Mellors, J. Condra, J. Chodakewitz, 2000, Annals of Internal Medicine.

Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals

V. Johnson, D. Kuritzkes, J. Bartlett, 1997, AIDS.

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)

C. Katlama, A. Lazzarin, P. Morlat, 2010, Journal of the International AIDS Society.

Risk of COVID-19 after natural infection or vaccination

Nicole L. Nollen, Eric A. Meyerowitz, Waseem M. Chughtai, 2023, EBioMedicine.